China’s histology market is one of the biggest in Asia Pacific and expected to be

second after Japan in 2010

China’s histology market is worth nearly USD33 million in 2007 and expected to grow by over 16%
CAGR over the next 3 years to reach USD50 million in 2010.

Clearstate’s detailed study on histology market demand in Asia Pacific (ex-Japan) revealed that China
has the highest volume of histology tests conducted in the region reaching 12 million stains in 2007.
China is close to Australia in terms of histology market value at USD33 million in 2007, but the rising
population affluence leading to soaring demand for advanced cancer testing is expected to push
China ahead to the number one spot in Asia (ex-Japan), reaching USD 50 million by 2010.

Clearstate’s study on Histology or Anatomic China: Total Histology Market value

(2007) – USD 33 million
Pathology included three main segments – Pre-
analytical (Equipment and Consumables), Primary Pre-
Staining (H&E and SS stains) and Advanced Staining analytical
15%
(IHC stains and ISH tests). Primary stains segment
represents the bulk of the histology market with 63% Advanced
stains Primary
share, where most of it comprised of H&E stains. 22% stains
Pre-analytical represents 15% of market share, where 63%
half of these are from instrument sales. Advanced
stains segment has 22% share of total histology
market, where over 85% of the value is attributed to
IHC stains.

Clearstate estimated that there are close 2,000 hospitals in China conducting histology tests. Almost
all of these are Class III government hospitals, while a small number are Class IIa facilities in tier 1
Chinese cities. The majority of these hospital-based laboratories conduct manual H&E tests. Only
about 12% or 260 hospitals-based laboratories conduct Advanced Staining and out of these, 15 are
high volume facilities with over 15,000 IHC stains conducted a year. Top 5 facilities in China are:

Beijing Cancer Institute Hospital

Beijing Xiehe Hospital

Nanjing Cancer Hospital

Shanghai Ruijin Hospital

Youyi Hospital

The overall prospect of Histology testing in China is bullish with expected double digit growth. IHC is
likely to be the strongest growth segment. Demand for IHC is high due to greater access to healthcare
to the general population, rising affluence and awareness. IHC is expected to emerge as the largest
segment in value terms in 5 years time.

Aside from covering Histology in detail in China, Clearstate’s Histology series also include in-depth
and comprehensive market opportunity studies in 13 other markets in Asia Pacific. For more
information on Clearstate’s Histology series and others, please contact info@clearstate.com or call
+65 63035030.

www.clearstate.com
About Clearstate

Clearstate, a niche healthcare consultancy, offers strategic advisory and intelligence services to help
medical devices, healthcare services, pharmaceutical and biotechnology firms understand their current
and potential markets, implement pragmatic and innovative strategies to ultimately tap into new growth
opportunities. Our approach to engagements is centred on thorough analysis of fact-based intelligence
and seasoned understanding of markets, practical strategy recommendations and implementations. We
provide accurate, reliable and comprehensive intelligence on medical device usage and demand across
Asia Pacific. We deliver actual and up-to-date placement, usage and consumption data for devices,
equipment and consumables found in healthcare and commercial settings.

For more information, please visit Clearstate at www.clearstate.com or call +65 63035030.

www.clearstate.com